Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences develops FASN inhibitor drugs, led by denifanstat, for liver disease, acne and certain cancers. It last closed at $9.08 on Nov 20, down 5.61% on the day. The next earnings report for SGMT is expected around Wed, Mar 10, 2027. For the quarter ended Sep 2026, SGMT reported EPS of -$0.31. Over its last 8 reports the stock moved an average of 8.4% the session after earnings. Over the last 12 months SGMT insiders bought $0 of stock on the open market and sold $4.9M, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From SGMT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on SGMT
Technical AnalysisPrices may be delayed
The stock is 12% below its 20 day and 8% below its 50 day average. It is 14% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the swing low (Aug 14) at $9.07, and the nearest resistance the Pivot at $9.10.
| RSI (14) | 42.27 | Middle of its range | Neutral |
| MACD | 0.04 | Below its signal line | Bearish |
| Stochastic | 26.4 | Middle of its range | Neutral |
| ADX (14) | 17.8 | No clear trend | |
| Williams %R | -90.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -164.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −7.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.68 | Typical daily range, 7.5% of price |
| RSI (14) | 51.68 | Middle of its range | Neutral |
| MACD | 0.60 | Below its signal line | Bearish |
| Stochastic | 58.8 | Middle of its range | Neutral |
| ADX (14) | 27.5 | Trending up | |
| Williams %R | -60.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 6.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −16.5% | Change over 10 sessions | Bearish |
| ATR (14) | $1.40 | Typical daily range, 15.4% of price |
What happened before
See how SGMT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SGMT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options FlowPrices may be delayed
90DNo whale options trades in SGMT in the last 90 days.
SGMT Institutional Ownership
Full report →- ▲107 buying vs 43 selling
- ▲Shares held by funds +36.7%
- ▲Funds holding +32
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 154 | 122 | +26.2% |
| In funds' top 10 | 3 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 50 / 57 | 57 / 36 | +15.1% |
| Reduced / sold out | 23 / 20 | 10 / 24 | +26.5% |
| Put/call ratio | 11.31 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
SGMT Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 14 | George KembleDirector | Sale plan | 350,987 | $10.23 | $3.6M |
| Aug 11 | George KembleDirector | Sale plan | 20,206 | $9.95 | $201K |
| Jul 20 | George KembleDirector | Sale plan | 18,844 | $7.46 | $141K |
| Jul 20 | Elizabeth RozekChief Legal & Admin. Officer | Sale | 10,545 | $7.76 | $82K |
| Jul 20 | David HappelPresident & CEO | Sale | 64,051 | $7.76 | $497K |
| Feb 10 | Elizabeth RozekChief Legal & Admin. Officer | Sale | 2,622 | $5.36 | $14K |
From SEC Form 4 filings by SGMT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SGMT is in one of them and how their past SGMT trades turned out.
SGMT News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SGMT in an article yet. Here's the latest on the wider market.
- Sagimet: New Acne Medication In 40 Years (Initiating With A Buy)
- Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
- Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than
About Sagimet Biosciences
Sagimet Biosciences is a biopharmaceutical company based in Foster City, California, that develops drugs called FASN inhibitors. Its lead candidate, denifanstat, is a pill taken by mouth once a day that is being studied for MASH, a serious form of fatty liver disease, along with acne and certain cancers. A second candidate, TVB-3567, is in early human testing for acne. The company aims these medicines at patients with metabolic and liver conditions, and a licensee in China is developing denifanstat for acne.
- Headquarters
- Foster City, CA



